Literature DB >> 17707694

Plasma exchange in critically ill patients with sickle cell disease.

C Boga1, I Kozanoglu, H Ozdogu, Emel Ozyurek.   

Abstract

Red cell exchange transfusion is the recommended therapy for patients with sickle cell disease who have complicated vaso-occlusive episodes. However, the role of the therapeutic plasma exchange in the management of the potentially life-threatening complications in patients with sickle cell disease is not well known. To determine whether plasma exchange had a cumulative effect on the red cell exchange in patients with sickle cell disease who developed multi-organ failure during the post red cell exchange period, we performed plasma exchange in the nine episodes of multi-organ failure of 7 patients with sickle cell anemia. The median age of those patients was 21 years (range, 9-50 years). The criterion of the multi-organ failure was defined as organ failure of two or more organs i.e. lung, liver, or renal, established according to Acute Physiological and Chronic Health Evaluation-II (APACHE-II) criteria. The average total plasma exchange volume was 1.0 times the patient's plasma volume. The patients had a good outcome, with a survival rate at 86% after one year of follow-up. Plasma exchange may have cumulative benefits in the treatment of severe illness in patients with sickle cell disease who underwent automatic red cell exchange therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17707694     DOI: 10.1016/j.transci.2006.12.009

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

1.  Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Authors:  Enrico M Novelli; Gregory J Kato; Mariana E Hildesheim; Suchitra Barge; Michael P Meyer; Jay Lozier; Andrea Cortese Hassett; Margaret V Ragni; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

2.  Effect of Hereditary Hemochromatosis Gene H63D and C282Y Mutations on Iron Overload in Sickle Cell Disease Patients.

Authors:  Yunus Kasım Terzi; Tuğçe Bulakbaşı Balcı; Can Boğa; Zafer Koç; Zerrin Yılmaz Çelik; Hakan Özdoğu; Sema Karakuş; Feride İffet Şahin
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

3.  Fat Embolism Syndrome in Sickle Cell Disease.

Authors:  Dimitris A Tsitsikas; Jessica Vize; Jibril Abukar
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.